MHRA approves Sharp’s clinical services center in Wales

By Maggie Lynch contact

- Last updated on GMT

(Image: Getty/Eivaisla)
(Image: Getty/Eivaisla)

Related tags: Sharp clinical packaging, Mhra, Clinical development, Wales, facility, Service

Sharp’s clinical services center is approved by the MHRA and now ready to offer services for serialization and trial management while reducing carbon footprint with the addition of solar panel systems.

After an inspection by the Medicines and Healthcare Product Regulatory Agency (MHRA), Sharp will now offer clinical trial and commercial services at its $12.67m (£9.7m) Clinical Services Center of Excellence​ in Rhymney, Wales.

The center will enable Sharp to offer integrated services such as serialization and interactive response technology (IRT) solutions for clinical trial management. The new facility also triples its clinical service capacity.

IRT solutions offered at the center are made available after Sharp recently invested $650,000 in the technology​ in an aim to ensure proper supply allocations for its clinical trials. At the time, Sharp stated that the addition of IRT mitigates the potential cost of overproduction in clinical trials.

Frank Lis, president of Sharp Clinical Services, said in a statement that the facility will be able to provide full-service support to meet the growing global demand for Phase III clinical trials and commercial services.

Sharp has additionally invested in a solar panel system to generate approximately 20% of its total annual electricity requirements at the site. This system will reduce the company’s carbon footprint and improve environmental performance.

Not long before the completion and approval of the Welsh site, Sharp completed an expansion of its clinical facility in Bethlehem, PA​ in the US to refit the facility and relocate services from the company’s previous Phoenixville site.

The clinical services company received the MHRA approval just as it celebrated its 30th ​year in clinical operations in the UK.

Related news

Show more

Related products

show more

Import Risks & Clinical Supply Depots

Import Risks & Clinical Supply Depots

Catalent Pharma Solutions | 07-Nov-2018 | Case Study

A sponsor running a clinical trial in Israel arranged to ship their clinical trial product from Europe to a depot in Israel. With the protocol based in...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 05-Nov-2018 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

Baxter’s Oncology Contract Manufacturing

Baxter’s Oncology Contract Manufacturing

Baxter BioPharma Solutions | 29-Aug-2018 | Product Brochure

Baxter BioPharma Solutions’ FOYA award-winning facility in Halle/Westfalen, Germany, offers state-of-the-art parenteral cGMP manufacturing at one location,...

Discover Fermion’s new API unit 4 in Hanko

Discover Fermion’s new API unit 4 in Hanko

Recorded the 04-Sep-2018 | Webinar

Join this webinar to learn more about Fermion’s new manufacturing unit 4 at the Hanko site. This webinar will provide virtual tour to our new state of...

Related suppliers

Follow us

Products

View more

Webinars